NRX Pharmaceuticals, Inc. (NRXP) stock
Close on Nov 12, 2026Market cap $98.71MP/E –Yield –
NRX Pharmaceuticals, Inc. reported revenue of $3.39M for the twelve months to Jun 30, 2026. At the latest close the market valued the company at $98.71M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $98.71M
- P/E ratio
- –
- Price to sales
- 29.09
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $3.39M
- Net income
- -$23.48M
- EPS, diluted
- -$0.73
- Book value per share
- -$0.00
- Diluted shares
- 38M
Trading
- Previous close
- $2.44
- Open
- $2.43
- Day's range
- $2.25 – $2.44
- Volume
- 605,046
- Average volume (20 days)
- 1,775,441
- Beta (5 years)
- 1.05
- 52-week range
- $1.62 – $5.05
- RSI (14 days)
- 39.5
- Volatility (1 year)
- 87.5%
- Relative volume
- 0.57×
- WACC
- 10.2%
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | NRXP | S&P 500 | Difference | NRXP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -20.0% | -2.7% | −17.3 pts | ||
| 3 months | -32.1% | -1.7% | −30.4 pts | ||
| Year to date | -15.9% | +11.9% | −27.8 pts | ||
| 1 year | -13.6% | +12.0% | −25.6 pts | ||
| 3 years | -30.9% | +78.2% | −109.1 pts | -11.6% | +21.2% |
| 5 years | -96.3% | +73.2% | −169.6 pts | -48.4% | +11.6% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases NRX Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- Update
- Results
- News
- News
About NRX Pharmaceuticals
Pharmaceutical Preparations
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops and distributes novel therapeutics for central nervous system disorders. Through its operating subsidiary, NeuroRx, Inc., the company focuses on treatments for conditions such as suicidal depression, chronic pain, post-traumatic stress disorder, and schizophrenia. Its lead drug candidates include preservative-free ketamine formulations (NRX-100 and KETAFREE™) and NRX-101, an oral combination therapy targeting neuroplasticity pathways. In addition, NRx operates a medical services segment through its majority-owned subsidiary, HOPE Therapeutics, Inc., which delivers interventional psychiatric care using neuromodulatory devices, neuroplastic drugs, digital therapeutics, and hyperbaric therapy. Its primary end customers are patients suffering from severe psychiatric and neurological conditions.
Company profile, executives and historyNRX Pharmaceuticals stock: common questions
What is NRX Pharmaceuticals's stock price?
NRXP closed at $2.28 on Nov 12, 2026, down 6.56% on the day. Over the past 52 weeks it traded between $1.62 and $5.05.
What is NRX Pharmaceuticals's market cap?
NRX Pharmaceuticals was worth $98.71M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is NRXP's P/E ratio?
NRX Pharmaceuticals lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.73), so it has no meaningful P/E ratio.
How much revenue does NRX Pharmaceuticals make?
NRX Pharmaceuticals reported revenue of $3.39M for the twelve months to Jun 30, 2026.
Does NRX Pharmaceuticals pay a dividend?
No. NRX Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has NRXP stock performed over the past year?
Including dividends, NRXP returned -13.6% over the past year, against +12.0% for the S&P 500.
How many NRXP shares are sold short?
10M shares were sold short at the latest FINRA report, 28.64% of the float, or 4.6 days of average trading volume.
Who are NRX Pharmaceuticals's competitors?
Companies most similar to NRX Pharmaceuticals by business, industry and size include VTGN, OVID, XENE, KRSA, LPCN.
See a number that looks wrong?